-
公开(公告)号：EP3142698A4
公开(公告)日：2018-03-14
申请号：EP15791992
申请日：2015-05-13
申请人： ONCOMED PHARM INC
IPC分类号： A61K39/395 , C07K16/00 , C12N5/07
CPC分类号： C07K16/2803 , A61K38/00 , A61K2039/505 , C07K14/70503 , C07K16/2818 , C07K16/30 , C07K2317/76 , C07K2319/30 , C07K2319/32 , C07K2319/60 , C07K2319/70 , C07K2319/74
摘要： Binding agents that modulate the immune response are disclosed. The binding agents may include antibodies, soluble receptors, and/or polypeptides. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.
-
公开(公告)号：EP2906295A4
公开(公告)日：2016-06-01
申请号：EP13847229
申请日：2013-10-15
申请人： ONCOMED PHARM INC
发明人： HASTINGS PAUL JAMES
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
-
公开(公告)号：EP2331136A4
公开(公告)日：2013-01-23
申请号：EP09817004
申请日：2009-09-28
申请人： ONCOMED PHARM INC
发明人： GURNEY AUSTIN L , SATO AARON KEN , AXELROD FUMIKO TAKADA , HOEY TIMOTHY CHARLES , SATYAL SANJEEV H , MITRA SATYAJIT SUJIT KUMAR
IPC分类号： A61K39/395 , A61P35/00 , C07K16/28
CPC分类号： C07K16/28 , A61K31/00 , A61K31/337 , A61K31/7068 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30 , G01N33/5011 , A61K2300/00
摘要： Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
摘要翻译： 提供了新的抗癌剂，包括但不限于与人类卷曲蛋白受体结合的抗体。 还鉴定了适合作为抗癌剂靶标的人类卷曲蛋白受体内的新表位。 还提供了使用所述试剂或抗体的方法，例如使用所述试剂或抗体抑制Wnt信号传导和/或抑制肿瘤生长的方法。
-
公开(公告)号：EP2307459A4
公开(公告)日：2012-07-18
申请号：EP09794822
申请日：2009-07-08
申请人： ONCOMED PHARM INC
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/28 , A61K31/337 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/10 , C07H21/04 , C07K14/435 , C07K14/71 , C07K16/22 , C07K16/30 , C07K16/3046 , C07K16/462 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N5/0693 , C12N5/12 , C12N15/63 , C12N15/79 , C12N2501/998
摘要： The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
-
5.发明公开NOTCH-BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF 有权NOTCH-BINDENDE WIRKSTOFFE UND ANTAGONISTEN SOWIE VERFAHREN ZU IHRER VERWENDUNG
公开(公告)号：EP2307051A4
公开(公告)日：2012-07-18
申请号：EP09794821
申请日：2009-07-08
申请人： ONCOMED PHARM INC
发明人： GURNEY AUSTIN L , HOEY TIMOTHY CHARLES , HTUN VAN DER HORST EDWARD THEIN , SATO AARON KEN , LIU YUAN CHING , BRUHNS MAUREEN FITCH , LEWICKI JOHN A
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/28 , A61K31/337 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/10 , C07H21/04 , C07K14/435 , C07K14/71 , C07K16/22 , C07K16/30 , C07K16/3046 , C07K16/462 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N5/0693 , C12N5/12 , C12N15/63 , C12N15/79 , C12N2501/998
摘要： The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
摘要翻译： 本发明涉及用于表征，诊断和治疗癌症的组合物和方法。 特别地，本发明提供了用于癌症的诊断，表征，预后和治疗以及特异性靶向癌症干细胞的方法和方法。 本发明提供了与人Notch受体的细胞外结构域的非配体结合膜近端区域特异性结合并抑制肿瘤生长的抗体。 本发明还提供了一种治疗癌症的方法，所述方法包括施用治疗有效量的特异性结合人Notch受体蛋白的细胞外结构域的非配体结合膜近端区域并抑制肿瘤生长的抗体。
-
公开(公告)号：EP2066694A4
公开(公告)日：2010-05-05
申请号：EP07838966
申请日：2007-09-28
申请人： ONCOMED PHARM INC
发明人： GURNEY AUSTIN , HOEY TIMOTHY , SATYAL SANJEEV , AXELROD FUMIKO
CPC分类号： A61K39/39558 , A61K31/4745 , A61K31/513 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61N5/10 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3046 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , A61K2300/00
-
公开(公告)号：EP3253890A4
公开(公告)日：2018-06-27
申请号：EP16747162
申请日：2016-02-03
申请人： ONCOMED PHARM INC
发明人： GURNEY AUSTIN L
CPC分类号： A61K38/19 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K14/00 , C07K14/52 , C07K14/525 , C07K14/7151 , C07K16/18 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2319/30 , C12N15/00 , C12N15/62 , C12Q1/68
摘要： Polypeptides and agents that bind a TNF receptor superfamily protein are disclosed, particularly agents that specifically bind GITR, OX40, or CD40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising GITRL, OX40L, or CD40L and/or bispecific agents. Also disclosed are methods of using the polypeptides or agents for inducing and/or enhancing the immune response, as well as methods for the treatment of diseases such as cancer.
-
公开(公告)号：EP2331136B1
公开(公告)日：2018-01-10
申请号：EP09817004
申请日：2009-09-28
申请人： ONCOMED PHARM INC
发明人： GURNEY AUSTIN L , SATO AARON KEN , AXELROD FUMIKO TAKADA , HOEY TIMOTHY CHARLES , SATYAL SANJEEV H , MITRA SATYAJIT SUJIT KUMAR
IPC分类号： A61K39/395 , A61P35/00 , C07K16/28
CPC分类号： C07K16/28 , A61K31/00 , A61K31/337 , A61K31/7068 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30 , G01N33/5011 , A61K2300/00
摘要： Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
-
公开(公告)号：EP3087099A4
公开(公告)日：2017-07-19
申请号：EP14874789
申请日：2014-12-22
申请人： ONCOMED PHARM INC
CPC分类号： C07K16/3007 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K14/70532 , C07K2317/34 , C07K2317/76 , C07K2319/30
-
公开(公告)号：EP2788378A4
公开(公告)日：2015-09-09
申请号：EP12854925
申请日：2012-12-07
申请人： ONCOMED PHARM INC
IPC分类号： A61K39/395 , A61K31/18 , A61P35/00 , C07K16/28
CPC分类号： A61K39/3955 , A61K31/18 , A61K38/177 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/28 , C07K16/2896 , A61K2300/00
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.015 秒)
